Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

The monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage ...

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...

Eli Lilly and Novo Nordisk are cutting prices for popular weight-loss drugs in deals struck with the Trump administration, ...

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday.

The Trump administration announced its newest pharmaceutical agreement under its Most Favored Nation policy Thursday, ...

Experimental pill versions of GLP-1 weight loss drugs by Novo Nordisk and Eli Lilly will receive FDA priority review. Read ...

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

Weight loss drugs are set to become a disproportionate share of Lilly's business.

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.